Novo Nordisk submit new drug application for liraglutide in Japan « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Novo Nordisk submit new drug application for liraglutide in Japan

Posted on July 16, 2008 by crimsoncanary

Novo Nordisk have submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for the approval of liraglutide, a once-daily human GLP-1 analogue, for the treatment of people with type 2 diabetes. The drug is under review in the US and EU.

Filed under: Uncategorized | Tagged: agonist, GLP-1, Glucagon-like peptide 1, liraglutide, NN-2211, NN2211, Novo Nordisk

« Phase II data show 5HT1D agonist MAP0004 is effective in Migraine Nile Therapeutics begin Phase IIa with CD-NP in Heart Failure Patients »

Leave a Reply